Zelira Secures US$33m Strategic Investment to Advance HOPE® 1 Autism Therapy

Zelira Therapeutics ( (AU:ZLD) ) just unveiled an update.

Zelira Therapeutics has secured binding agreements with TGC Biotechnology Fund (ThirdGate Capital) for a US$32.98 million equity investment into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million and Zelira’s post-money stake at roughly US$26.19 million. The deal will leave ThirdGate holding 50% of the HOPE® 1 SPV on a fully diluted basis, with Zelira retaining 39.7%, and is expected to fully fund an accelerated U.S. development program via the FDA’s 505(b)(2) pathway for HOPE® 1 in Phelan-McDermid Syndrome co-morbid with autism, a rare, genetically defined subset of autism spectrum disorder that may qualify for orphan drug designation. The funding underscores investor confidence in HOPE® 1’s clinical and commercial potential, strengthens Zelira’s balance sheet exposure to a key asset, and positions the company to advance first-in-human trials in the United States, with potential long-term benefits from exclusivity and regulatory incentives if orphan status is granted.

The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.33 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

More about Zelira Therapeutics

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is a global biopharmaceutical company focused on developing clinically validated cannabis-based medicines, with a particular emphasis on neurological and rare diseases such as autism spectrum disorder. The company advances proprietary formulations, including its HOPE® 1 product, through regulated pathways in major markets, targeting underserved patient populations and leveraging real-world clinical data to support regulatory approvals.

Average Trading Volume: 4,636

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$4.28M

For detailed information about ZLD stock, go to TipRanks’ Stock Analysis page.